{ "slug": "tonix-pharmaceuticals-holding-corp", "canonical_name": "Tonix Pharmaceuticals Holding Corp", "website": null, "ats": "greenhouse", "top_startup": false, "top_startup_sources": [], "total_active_jobs": 17, "verified_benefits": { "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "verified_count": 17, "last_verified": "2026-06-13T01:18:42.546Z" }, "awards": null, "jobs": [ { "id": "076f9f44f246f0b540e082f0b12e48b8", "title": "Manager, Corporate Strategy and CEO Initiatives", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 90000, "salary_max": 150000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 90000, "base_salary_max": 150000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-06-04T15:41:23.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4272302009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Manager, Corporate Strategy and CEO Initiatives Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Manager, Corporate", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 7, "years_experience_max": null, "role_function": "product", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "22eb7400d93a2228a5baebd96c302a3f", "title": "Senior Manager, Cost Accounting", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA", "country": "US", "employment_type": "contract", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 100000, "salary_max": 150000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 100000, "base_salary_max": 150000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-21T17:03:55.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4248421009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Manager, Cost Accounting Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "finance", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "f0ce14bd47d44c234dc4d1bfb2dda4fa", "title": "Postdoctoral Fellowship-Immunology", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Frederick, MD 21701", "country": "unknown", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 3, "salary_min": 75000, "salary_max": 95000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 75000, "base_salary_max": 95000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-18T14:37:47.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4245264009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Postdoctoral Fellowship-Immunology Frederick, MD 21701 Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking a highly motivated and", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "6445f086c535ac6e27d289212fcec87f", "title": "Associate Scientist I, Immunology", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Frederick, MD 21701", "country": "unknown", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 3, "salary_min": 50000, "salary_max": 70000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 50000, "base_salary_max": 70000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-18T14:29:33.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4245265009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Associate Scientist I, Immunology Frederick, MD 21701 Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking an Associate", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "19f128092c2078d54205dc1b98eb6237", "title": "Senior Manager, Total Rewards", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 130000, "salary_max": 170000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 130000, "base_salary_max": 170000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-05-05T19:32:12.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4239809009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Manager, Total Rewards Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Manager, Total Rewards", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "43c521ed362b3cbb500a34ca41435de7", "title": "Sr. Director, Brand Marketing", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 190000, "salary_max": 285000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 190000, "base_salary_max": 285000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-24T12:36:50.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4227536009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Sr. Director, Brand Marketing Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Director, Brand Marketing", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "3c24ac7bb567169977728f315265cb92", "title": "Associate Director, Regulatory Affairs", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA or Fort Worth, TX", "country": "US", "employment_type": "full_time", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 190000, "salary_max": 200000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 190000, "base_salary_max": 200000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-14T13:12:19.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4215536009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Associate Director, Regulatory Affairs Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA or Fort Worth, TX Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 20, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "1b326dea67a7a33623858526b1b4d5b5", "title": "Manager, Quality Systems & Administration", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "North Dartmouth, MA", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 110000, "salary_max": 145000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 110000, "base_salary_max": 145000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-13T18:42:00.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4214661009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Manager, Quality Systems & Administration North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview: The Manager, Quality Systems", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 8, "years_experience_max": 12, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 10, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "68bb3e89493f97efe7d4b0ce5fd3e5e1", "title": "Pharmacovigilance Scientist", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 124000, "salary_max": 170000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 124000, "base_salary_max": 170000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-04-02T15:00:03.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4205666009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Pharmacovigilance Scientist Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking an experienced Pharmacovigilance Scientist", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "f06685f8e74b0dfbf35a29a875ace009", "title": "Senior Director of CMC and Nonclinical Program Management", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "North Dartmouth, MA", "country": "US", "employment_type": "contract", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 223814, "salary_max": 279767, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 223814, "base_salary_max": 279767, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-19T21:12:55.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4186570009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Director of CMC and Nonclinical Program Management North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "finance", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "79078570025ba379266174208ccd6737", "title": "Director, Regulatory Affairs - Infectious Disease", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 150000, "salary_max": 240000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 150000, "base_salary_max": 240000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-11T18:51:58.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4180874009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Regulatory Affairs - Infectious Disease Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Director, Regulatory", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 8, "years_experience_max": 12, "role_function": "other", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 20, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "256f7ef8e33d2e98558295760474e478", "title": "Manager, Trade & Market Access", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "contract", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 90000, "salary_max": 150000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 90000, "base_salary_max": 150000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-05T16:49:40.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4170833009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Manager, Trade & Market Access Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Manager of Trade", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "marketing", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "d9dd77bba2763c86b4e97f912ac69625", "title": "Scientist II, Animal Model Development", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Frederick, MD", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 70000, "salary_max": 120000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 70000, "base_salary_max": 120000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-03-05T14:33:38.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4170744009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Scientist II, Animal Model Development Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix Research and Development Center", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "doctorate", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "a771ce567d3aa976d8a681c6f9939324", "title": "Thought Leader Liaison (TLL), West Region", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "United States", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 130000, "salary_max": 200000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 130000, "base_salary_max": 200000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-02-12T16:46:05.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4130652009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Thought Leader Liaison (TLL), West Region United States Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Associate Director, Thought", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "mid", "years_experience_min": 3, "years_experience_max": 7, "role_function": "engineering", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 75, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "none", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "7889073eeed97ffb0af8f3c7a5a54399", "title": "VP, Clinical Development - Infectious Disease", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Frederick, Maryland or Berkeley Heights, New Jersey", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 250000, "salary_max": 350000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 250000, "base_salary_max": 350000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-01-20T21:03:17.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4108447009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "VP, Clinical Development - Infectious Disease Frederick, Maryland or Berkeley Heights, New Jersey Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 15, "years_experience_max": null, "role_function": "engineering", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "none", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "dead2e586561377764f2a1fe30e9a500", "title": "Senior Specialist, Regulatory Operations", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Frederick, MD", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 70000, "salary_max": 130000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 70000, "base_salary_max": 130000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": false, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2026-01-15T15:31:52.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4106035009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Senior Specialist, Regulatory Operations Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Specialist, Regulatory Operations, will", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "senior", "years_experience_min": 5, "years_experience_max": 9, "role_function": "operations", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": 10, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "bachelors", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] }, { "id": "5c6b235f210f6bca2c418a52d210c197", "title": "Director, Commercial Operations and Analytics", "employer_name": "Tonix Pharmaceuticals Holding Corp", "employer_slug": "tonix-pharmaceuticals-holding-corp", "location_text": "Berkeley Heights, NJ", "country": "US", "employment_type": "unknown", "remote_status": "unspecified", "remote_status_source": null, "remote_status_enriched_at": null, "days_in_office": null, "timezone_overlap_hours": 6, "salary_min": 180000, "salary_max": 230000, "salary_min_source": null, "salary_max_source": null, "salary_currency": "USD", "salary_type": "base_plus_commission", "salary_type_source": null, "salary_type_enriched_at": null, "salary_period": "year", "base_salary_min": 180000, "base_salary_max": 230000, "salary_disclosed": true, "equity_included": true, "equity_included_source": null, "equity_type": [ "options" ], "k401_match": "yes", "match_401k_pct": null, "match_401k_pct_source": null, "k401_match_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_match_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "k401_contribution_source_url": "https://www.askebsa.dol.gov/FOIA%20Files/2024/Latest/F_SCH_H_2024_Latest.zip", "k401_contribution_source_fields": [ "EMPLR_CONTRIB_INCOME_AMT" ], "profit_sharing": false, "bonus_offered": true, "mental_health_support": null, "childcare_subsidy": null, "fertility_family_building_benefits": null, "adoption_assistance_offered": null, "surrogacy_assistance_offered": null, "learning_budget_offered": null, "relocation_assistance": null, "top_startup_sources": [], "posted_at": "2025-12-15T20:32:13.000Z", "apply_url": "https://job-boards.greenhouse.io/tonixpharmaceuticals/jobs/4077936009", "apply_url_verified": false, "ats": "greenhouse", "url_last_checked_alive": null, "removed_at": null, "description_excerpt": "Director, Commercial Operations and Analytics Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Director, Commercial Operations", "parental_leave_weeks": null, "non_birth_parent_leave_weeks": null, "parental_leave_weeks_source": null, "non_birth_parent_leave_weeks_source": null, "parental_leave_source_url": null, "pto_days": null, "unlimited_pto": false, "sabbatical_eligible": false, "family_friendly_score": 44, "benefit_verified": true, "benefit_last_verified": "2026-06-13T01:18:42.546Z", "hire_states_allowed": [], "state_eligibility_source": null, "state_eligibility_enriched_at": null, "llm_quality_pass_at": null, "seniority": "staff_plus", "years_experience_min": 10, "years_experience_max": null, "role_function": "data", "employer_industry": null, "employer_size": null, "quality_score": 55, "travel_pct": null, "requires_shift": null, "shift_type": "unknown", "shift_type_source": null, "weekend_work": "unknown", "weekend_work_source": null, "relocation_assistance_source": null, "contractor_w2": "unknown", "required_timezone": null, "fertility_family_building_benefits_source": null, "mental_health_support_source": null, "adoption_assistance_offered_source": null, "childcare_subsidy_source": null, "learning_budget_offered_source": null, "surrogacy_assistance_offered_source": null, "cover_letter_required": null, "cover_letter_required_source": null, "assessment_required": null, "assessment_required_source": null, "application_deadline": null, "application_deadline_source": null, "visa_sponsorship": false, "us_citizenship_required": false, "security_clearance": "none", "education_required": "masters", "roll_up_count": null, "roll_up_total_locations": null, "explanations": [] } ], "json_ld": [ { "@context": "https://schema.org", "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp", "url": "https://fewerjobs.com/employers/tonix-pharmaceuticals-holding-corp", "sameAs": [] }, { "@context": "https://schema.org", "@type": "ItemList", "name": "Tonix Pharmaceuticals Holding Corp open jobs", "itemListElement": [ { "@type": "ListItem", "position": 1, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-corporate-strategy-and-ceo-initiatives-076f9f44", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Manager, Corporate Strategy and CEO Initiatives", "description": "

Manager, Corporate Strategy and CEO Initiatives at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Manager, Corporate Strategy and CEO Initiatives Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Manager, Corporate

", "datePosted": "2026-06-04T15:41:23.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "076f9f44f246f0b540e082f0b12e48b8" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 90000, "maxValue": 150000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 84 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-corporate-strategy-and-ceo-initiatives-076f9f44" } }, { "@type": "ListItem", "position": 2, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-manager-cost-accounting-22eb7400", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Manager, Cost Accounting", "description": "

Senior Manager, Cost Accounting at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA - Senior Manager, Cost Accounting Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

", "datePosted": "2026-05-21T17:03:55.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "22eb7400d93a2228a5baebd96c302a3f" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights, NJ or Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 100000, "maxValue": 150000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-manager-cost-accounting-22eb7400" } }, { "@type": "ListItem", "position": 3, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/postdoctoral-fellowship-immunology-f0ce14bd", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Postdoctoral Fellowship-Immunology", "description": "

Postdoctoral Fellowship-Immunology at Tonix Pharmaceuticals Holding Corp - Frederick, MD 21701 - Postdoctoral Fellowship-Immunology Frederick, MD 21701 Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking a highly motivated and

", "datePosted": "2026-05-18T14:37:47.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "f0ce14bd47d44c234dc4d1bfb2dda4fa" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "unknown", "addressLocality": "Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 75000, "maxValue": 95000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/postdoctoral-fellowship-immunology-f0ce14bd" } }, { "@type": "ListItem", "position": 4, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/associate-scientist-i-immunology-6445f086", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Associate Scientist I, Immunology", "description": "

Associate Scientist I, Immunology at Tonix Pharmaceuticals Holding Corp - Frederick, MD 21701 - Associate Scientist I, Immunology Frederick, MD 21701 Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking an Associate

", "datePosted": "2026-05-18T14:29:33.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "6445f086c535ac6e27d289212fcec87f" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "unknown", "addressLocality": "Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 50000, "maxValue": 70000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/associate-scientist-i-immunology-6445f086" } }, { "@type": "ListItem", "position": 5, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-manager-total-rewards-19f12809", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Manager, Total Rewards", "description": "

Senior Manager, Total Rewards at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Senior Manager, Total Rewards Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Manager, Total Rewards

", "datePosted": "2026-05-05T19:32:12.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "19f128092c2078d54205dc1b98eb6237" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 130000, "maxValue": 170000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-manager-total-rewards-19f12809" } }, { "@type": "ListItem", "position": 6, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/sr-director-brand-marketing-43c521ed", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Sr. Director, Brand Marketing", "description": "

Sr. Director, Brand Marketing at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Sr. Director, Brand Marketing Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Director, Brand Marketing

", "datePosted": "2026-04-24T12:36:50.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "43c521ed362b3cbb500a34ca41435de7" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 190000, "maxValue": 285000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/sr-director-brand-marketing-43c521ed" } }, { "@type": "ListItem", "position": 7, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/associate-director-regulatory-affairs-3c24ac7b", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Associate Director, Regulatory Affairs", "description": "

Associate Director, Regulatory Affairs at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA or Fort Worth, TX - Associate Director, Regulatory Affairs Berkeley Heights, NJ or Frederick, MD or North Dartmouth, MA or Fort Worth, TX Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property

", "datePosted": "2026-04-14T13:12:19.000Z", "employmentType": "FULL_TIME", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "3c24ac7bb567169977728f315265cb92" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights, NJ or Frederick, MD or North Dartmouth" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 190000, "maxValue": 200000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/associate-director-regulatory-affairs-3c24ac7b" } }, { "@type": "ListItem", "position": 8, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-quality-systems-and-administration-1b326dea", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Manager, Quality Systems & Administration", "description": "

Manager, Quality Systems & Administration at Tonix Pharmaceuticals Holding Corp - North Dartmouth, MA - Manager, Quality Systems & Administration North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview: The Manager, Quality Systems

", "datePosted": "2026-04-13T18:42:00.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "1b326dea67a7a33623858526b1b4d5b5" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "North Dartmouth" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 110000, "maxValue": 145000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-quality-systems-and-administration-1b326dea" } }, { "@type": "ListItem", "position": 9, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/pharmacovigilance-scientist-68bb3e89", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Pharmacovigilance Scientist", "description": "

Pharmacovigilance Scientist at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Pharmacovigilance Scientist Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix is seeking an experienced Pharmacovigilance Scientist

", "datePosted": "2026-04-02T15:00:03.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "68bb3e89493f97efe7d4b0ce5fd3e5e1" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 124000, "maxValue": 170000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/pharmacovigilance-scientist-68bb3e89" } }, { "@type": "ListItem", "position": 10, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-director-of-cmc-and-nonclinical-program-management-f06685f8", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Director of CMC and Nonclinical Program Management", "description": "

Senior Director of CMC and Nonclinical Program Management at Tonix Pharmaceuticals Holding Corp - North Dartmouth, MA - Senior Director of CMC and Nonclinical Program Management North Dartmouth, MA Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix

", "datePosted": "2026-03-19T21:12:55.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "f06685f8e74b0dfbf35a29a875ace009" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "North Dartmouth" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 223814, "maxValue": 279767, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-director-of-cmc-and-nonclinical-program-management-f06685f8" } }, { "@type": "ListItem", "position": 11, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/director-regulatory-affairs-infectious-disease-79078570", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Regulatory Affairs - Infectious Disease", "description": "

Director, Regulatory Affairs - Infectious Disease at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Director, Regulatory Affairs - Infectious Disease Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Director, Regulatory

", "datePosted": "2026-03-11T18:51:58.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "79078570025ba379266174208ccd6737" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 150000, "maxValue": 240000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 96 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/director-regulatory-affairs-infectious-disease-79078570" } }, { "@type": "ListItem", "position": 12, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-trade-and-market-access-256f7ef8", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Manager, Trade & Market Access", "description": "

Manager, Trade & Market Access at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Manager, Trade & Market Access Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Manager of Trade

", "datePosted": "2026-03-05T16:49:40.000Z", "employmentType": "CONTRACTOR", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "256f7ef8e33d2e98558295760474e478" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 90000, "maxValue": 150000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/manager-trade-and-market-access-256f7ef8" } }, { "@type": "ListItem", "position": 13, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/scientist-ii-animal-model-development-d9dd77bb", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Scientist II, Animal Model Development", "description": "

Scientist II, Animal Model Development at Tonix Pharmaceuticals Holding Corp - Frederick, MD - Scientist II, Animal Model Development Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview Tonix Research and Development Center

", "datePosted": "2026-03-05T14:33:38.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "d9dd77bba2763c86b4e97f912ac69625" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 70000, "maxValue": 120000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "Doctorate", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/scientist-ii-animal-model-development-d9dd77bb" } }, { "@type": "ListItem", "position": 14, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/thought-leader-liaison-tll-west-region-a771ce56", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Thought Leader Liaison (TLL), West Region", "description": "

Thought Leader Liaison (TLL), West Region at Tonix Pharmaceuticals Holding Corp - United States - Thought Leader Liaison (TLL), West Region United States Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Associate Director, Thought

", "datePosted": "2026-02-12T16:46:05.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "a771ce567d3aa976d8a681c6f9939324" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 130000, "maxValue": 200000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 36 }, "educationRequirements": "no requirements", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/thought-leader-liaison-tll-west-region-a771ce56" } }, { "@type": "ListItem", "position": 15, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/vp-clinical-development-infectious-disease-7889073e", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "VP, Clinical Development - Infectious Disease", "description": "

VP, Clinical Development - Infectious Disease at Tonix Pharmaceuticals Holding Corp - Frederick, Maryland or Berkeley Heights, New Jersey - VP, Clinical Development - Infectious Disease Frederick, Maryland or Berkeley Heights, New Jersey Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position

", "datePosted": "2026-01-20T21:03:17.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "7889073eeed97ffb0af8f3c7a5a54399" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 250000, "maxValue": 350000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 180 }, "educationRequirements": "no requirements", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/vp-clinical-development-infectious-disease-7889073e" } }, { "@type": "ListItem", "position": 16, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-specialist-regulatory-operations-dead2e58", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Senior Specialist, Regulatory Operations", "description": "

Senior Specialist, Regulatory Operations at Tonix Pharmaceuticals Holding Corp - Frederick, MD - Senior Specialist, Regulatory Operations Frederick, MD Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Senior Specialist, Regulatory Operations, will

", "datePosted": "2026-01-15T15:31:52.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "dead2e586561377764f2a1fe30e9a500" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Frederick" } }, "baseSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 70000, "maxValue": 130000, "unitText": "YEAR" } }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options)", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 60 }, "educationRequirements": "Bachelors", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/senior-specialist-regulatory-operations-dead2e58" } }, { "@type": "ListItem", "position": 17, "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/director-commercial-operations-and-analytics-5c6b235f", "item": { "@context": "https://schema.org", "@type": "JobPosting", "title": "Director, Commercial Operations and Analytics", "description": "

Director, Commercial Operations and Analytics at Tonix Pharmaceuticals Holding Corp - Berkeley Heights, NJ - Director, Commercial Operations and Analytics Berkeley Heights, NJ Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti- Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X . *Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners. Position Overview The Director, Commercial Operations

", "datePosted": "2025-12-15T20:32:13.000Z", "employmentType": "OTHER", "identifier": { "@type": "PropertyValue", "name": "Tonix Pharmaceuticals Holding Corp", "value": "5c6b235f210f6bca2c418a52d210c197" }, "hiringOrganization": { "@type": "Organization", "name": "Tonix Pharmaceuticals Holding Corp" }, "jobLocation": { "@type": "Place", "address": { "@type": "PostalAddress", "addressCountry": "US", "addressLocality": "Berkeley Heights" } }, "estimatedSalary": { "@type": "MonetaryAmount", "currency": "USD", "value": { "@type": "QuantitativeValue", "minValue": 180000, "maxValue": 230000, "unitText": "YEAR" }, "description": "Base salary plus commission" }, "directApply": false, "jobBenefits": "401(k) match", "incentiveCompensation": "Equity (Options); Bonus", "experienceRequirements": { "@type": "OccupationalExperienceRequirements", "monthsOfExperience": 120 }, "educationRequirements": "Masters", "url": "https://fewerjobs.com/jobs/tonix-pharmaceuticals-holding-corp/director-commercial-operations-and-analytics-5c6b235f" } } ] } ] }